Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Mayne Pharma Group ( (AU:MYX) ).
Mitsubishi UFJ Financial Group, Inc. has become a substantial holder in Mayne Pharma Group Limited, acquiring a significant number of fully paid ordinary shares. This development indicates Mitsubishi UFJ’s increased influence in Mayne Pharma, potentially impacting the company’s governance and strategic decisions, given the substantial voting power now held by Mitsubishi UFJ.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
YTD Price Performance: 1.01%
Average Trading Volume: 978,817
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$407.9M
See more data about MYX stock on TipRanks’ Stock Analysis page.